Featured Grant Funding

  • Dr. Marcucci holds an R01 (CA102031) titled, “Pharmacological modulation of epigenetic changes in AML.” He also holds an award from the V Scholar Foundation titled, “Immunotherapeutic targeting of IL-1-RAP to eliminate leukemia stem cells (LSC) in Acute Myeloid Leukemia (AML).”
  • Dr. Muschen is supported by an NCI Outstanding Investigator Award (R35 CA 197628) and two R01s (CA137060, CA157644) and is also an HHMI scholar.
  • Dr. Carlesso holds an R01 (7R01DK097837) titled “Physiologic regulation of hematopoiesis by notch” that explores the role of Notch in inflammation and tumorigenesis.
  • Dr. Kortylewski holds an R01 in collaboration with Dr. Marcucci (CA213131) for targeting transcriptional regulators for immunotherapy of acute myeloid leukemia. The overall goal of this project is to dissect molecular and cellular mechanisms of CpG-STAT3decoy effect and then verify the therapeutic efficacy of optimized strategies against human and mouse models of leukemia.
  • Dr. Ya-Huei Kuo is the PI on an R01 (CA178387) titled, “HDAC8 Mediated Regulation of Acute Myeloid Leukemia Pathogenesis and Maintenance.” Dr. Kuo is also supported by another R01 award (CA205247) for a collaborative project titled, “Targeting microRNAs to eradicate leukemia stem cells.”
  • Dr. Ling Li has a career advancement award from the NIH (R00 CA184411) titled, “Role of the SIRT1 deacetylase in maintenance of FLT3/ITD positive AML stem cells.” His work is also supported by an award from the V Scholar Foundation, “Role of arginine methylation in maintenance of FLT3-ITD positive AML leukemia stem cells”